Graham Capital Management L.P. Purchases Shares of 21,249 AtriCure, Inc. (NASDAQ:ATRC)

Graham Capital Management L.P. purchased a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 21,249 shares of the medical device company's stock, valued at approximately $649,000.

Several other hedge funds have also recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. bought a new stake in shares of AtriCure during the 4th quarter valued at about $9,168,000. Kennedy Capital Management LLC boosted its holdings in shares of AtriCure by 29.8% during the 4th quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock worth $22,999,000 after buying an additional 172,648 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of AtriCure by 37.1% during the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock worth $18,922,000 after buying an additional 167,476 shares in the last quarter. Oberweis Asset Management Inc. bought a new stake in shares of AtriCure in the 4th quarter valued at $4,630,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of AtriCure by 24.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock valued at $21,398,000 after acquiring an additional 136,015 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

Insider Activity at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This represents a 25.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.50% of the stock is currently owned by insiders.

AtriCure Trading Up 2.4%

ATRC opened at $32.25 on Thursday. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The firm has a market capitalization of $1.60 billion, a PE ratio of -33.95 and a beta of 1.57. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The company's 50-day moving average is $32.50 and its 200 day moving average is $34.83.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The firm had revenue of $123.62 million during the quarter, compared to the consensus estimate of $122.92 million. During the same period in the prior year, the business posted ($0.28) earnings per share. The company's quarterly revenue was up 13.5% compared to the same quarter last year. As a group, research analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

ATRC has been the topic of several research analyst reports. JMP Securities reissued a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research note on Wednesday, April 30th. BTIG Research reissued a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Piper Sandler raised their target price on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. UBS Group dropped their price target on AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Finally, Needham & Company LLC cut their price target on AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.67.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.